Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biochip for detection of inflammatory bowel disease

26.01.2005


At the III International Symposium on Advanced Therapy for Chronic Inflammatory Bowel Disease, held in Madrid, the biotechnological company, Progenika, presented a DNA-chip the purpose of which is the optimisation of the diagnosis, prognosis and treatment of patients with inflammatory bowel disease (Crohn’s disease and Ulcerous Colitis).



The project developing the biochip, known as the IBDChip, was carried out with the collaboration of Dr. Miquel Sans of the Gastroenterology Service at the Barcelona Hospital Clínico and Dr. Carlos Cara of UCB Pharma. The biochip is currently analysing 46 mutations related to inflammatory bowel disease (EII) and will shortly begin clinical trials.

The polymorphisms analysed are diverse and enable the establishment of the risk of suffering from the disease, its prognosis and the response of the patient to the pharmacological treatment.


From a clinical practice viewpoint the implantation of the IBDchip has a twin usefulness: it enables the selection of the most suitable therapy for each patient and it also determines, in those family members of EII sufferers who wish to be tested, the degree of predisposition for developing the infirmity.

Inflammatory bowel disease (EII) includes Crohn’s Disease (CD) and Ulcerous Colitis (UC), disorders of particular importance in gastroenterology both amongst children and adults. The evidence for a genetic origin to the illness is a fact. Between 10 and 20 per cent of family members of CD and UC patients, also have these diseases. The IBDchip is an open tool which to date includes the polymorphisms associated in the literature with the disease, the predisposition to the disease nd its evolution. As new mutations are identified, these can be easily incorporated into the IBDchip for their analysis.

Progenika, a biotechnology company of the Basque Country, pioneer in this field in Spain, has already developed other, similar products. An example is the Lipochip developed for the Lácer pharmaceutical company and which diagnoses family hypercholesterolemia. The Lipochip was the first biochip to obtain European Commission certificate for its diagnostic use.

The Bloodchip, a biochip for genotyping blood donors, is another example. This biochip has recently started clinical trials in Spain, Germany, the UK, Holland and the Czech Republic using more than 4,000 donors.

Garazi Andonegi | EurekAlert!
Further information:
http://www.elhuyar.com
http://www.basqueresearch.com

More articles from Life Sciences:

nachricht Decoding the genome's cryptic language
27.02.2017 | University of California - San Diego

nachricht New risk factors for anxiety disorders
24.02.2017 | Julius-Maximilians-Universität Würzburg

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New pop-up strategy inspired by cuts, not folds

27.02.2017 | Materials Sciences

Sandia uses confined nanoparticles to improve hydrogen storage materials performance

27.02.2017 | Interdisciplinary Research

Decoding the genome's cryptic language

27.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>